RecruitingNot ApplicableNCT07360977

Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

A Composition Comprising Glucoraphanin, Myrosinase and a Buffered Solution for Use in the Treatment of Neurodegenerative Diseases

Sponsor

IRCCS Centro Neurolesi Bonino Pulejo

Enrollment

300 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

PARKINSON DISEASE (Disorder)Multiple Sclerosis (MS) - Relapsing-remitting Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases

Summary

Glucosinolates (GLs) are phytocompounds mainly found in the Cruciferae (Brassicacea) and Moringa oleifera plants. The hydrolysis of GLs by myrosinase led to the production of isothiocyanate (ITCs). ITCs consumption was associated with different health promoting effects, including to neuroprotective, anti-oxidant and anti-inflammatory capacities. In particular, they showed neuroprotective effects in experimental models of neurodegenerative diseases, including multiple sclerosis (MS) and Parkinson's disease (PD). From different GLs, different ITCs are originated. In particular, from glucoraphanin (GRA) the ITC sulforaphane (SFN) is obtained. The PI of the project is one of the proprietor of a patent (EP2908850B1) for the application of (Rs)-GRA with myrosinase in a buffered solution for the treatment of neurodegenerative diseases. The aim of this project is to evaluate the effects of the administration of bioactivated GRA in different cohorts of adult patients, affected by MS and PD, but also a cohort of pediatric patients affected by neuromuscolar and degenerative diseases. The effects of bioactivated (Rs)-GRA administration will be evaluated with a combination of clinical evaluations and a multiomic (metabolomic, genomic) approach.

Eligibility

Min Age: 1 YearMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a natural compound called glucoraphanin (found in broccoli sprouts) activated by an enzyme called myrosinase, to see if it can slow progression or reduce symptoms of Parkinson's disease or multiple sclerosis in adults, or improve health outcomes in children with certain metabolic conditions. **You may be eligible if...** - You are an adult with Parkinson's disease, diagnosed using UK Brain Bank criteria, aged 45–75, with stable symptoms for at least 3 months - OR you have relapsing-remitting multiple sclerosis (RRMS), are 18 or older, with a disability score (EDSS) of 5.5 or lower and stable disease for at least 30 days - OR you are a child aged 1–10 years (5–30 kg) who is clinically stable and not enrolled in other trials - Your medications have not changed in the 3 months before the study **You may NOT be eligible if...** - You have contraindications to MRI scanning - You have another serious neurological condition such as stroke, epilepsy, dementia, or psychiatric disorder - For MS patients: you had a relapse in the last 30 days, or your disease-modifying therapy changed in the past 3 months - Your cognitive score on the MMSE is very low (below 24) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.